Ontario Drug Benefit Formulary/ Comparative Drug Index

Similar documents
Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/ Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

UPDATE AF Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective March 26, 2012 SUMMARY OF CHANGES

UPDATE AX Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective August 29, 2013 SUMMARY OF CHANGES

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

UPDATE AU Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective May 31, 2013 SUMMARY OF CHANGES

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

UPDATE AA Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective September 15, 2011 SUMMARY OF CHANGES

UPDATE C Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective November 04, 2008 SUMMARY OF CHANGES

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

UPDATE AB Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 25, 2011 SUMMARY OF CHANGES

UPDATE AJ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective July 27, 2012 SUMMARY OF CHANGES

Ontario Drug Benefit Formulary/Comparative Drug Index

NB Drug Plans Formulary Update

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/ Comparative Drug Index

UPDATE B Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 01, 2008 SUMMARY OF CHANGES

UPDATE AZ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 31, 2013 SUMMARY OF CHANGES

BULLETIN # 74. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 17, 2013

UPDATE E Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective December 23, 2008 SUMMARY OF CHANGES

UPDATE F Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective 30 January, 2009 SUMMARY OF CHANGES

NB Drug Plans Formulary Update

Manager, PEI Drug Programs Date : December 7, 2009 Tel / Tél : (902) Fax / Téléc : (902)

UPDATE AE Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective February 29, 2012 SUMMARY OF CHANGES

Ontario Drug Benefit Formulary/Comparative Drug Index

UPDATE C Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective November 04, 2008 SUMMARY OF CHANGES

NB Drug Plans Formulary Update

BULLETIN # 73. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on July 17, 2013

Ontario Drug Benefit Formulary/Comparative Drug Index

Product Selection Committee / Comité de sélection des produits

BULLETIN # 78. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on July 17, 2014

SASKATCHEWAN FORMULARY COMMITTEE BULLETIN FOR THE UPDATE TO THE 56th EDITION OF THE SASKATCHEWAN FORMULARY

PEI Drug Programs. Issue October, 2006

Nova Scotia Pharmacare Programs Interchangeable Product Updates November 13, 2018 New Categories

Updates to the Alberta Health and Wellness Drug Benefit List

SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY

NB Drug Plans Formulary Update

SASKATCHEWAN FORMULARY COMMITTEE BULLETIN UPDATE TO THE 54th EDITION

SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY

New Interchangeable Products Approved and Benefit Status Within the Nova Scotia Pharmacare Programs March 2016

Updates to the Alberta Drug Benefit List. Effective February 1, 2018

UPDATE AT Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective April 30, 2013 SUMMARY OF CHANGES

BULLETIN # 84. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 22, 2015

BULLETIN # 89. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 20, 2016

Pharmacy Consultant, PEI Drug Programs Date : September 8, 2009 Tel / Tél : (902) Fax / Téléc : (902)

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

SASKATCHEWAN FORMULARY BULLETIN Update to the 60th Edition of the Saskatchewan Formulary

Ontario Drug Benefit Formulary/Comparative Drug Index

Updates to the Alberta Drug Benefit List. Effective June 1, 2018

BULLETIN # 90. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on January 25, 2017

4.7 Studies of Quality Holy Cross Hospital Bone Health Early Stage I ER/PR Positive Breast Cancer Patients December 13, 2017

NBPDP Formulary Update

Product Selection Committee / Comité de sélection des produits

Archived Content. This content was archived on June 24, 2013.

New Exception Status Benefits

BULLETIN # 98. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on April 19, 2018

BULLETIN # 80. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on January 19, 2015

BULLETIN # 79. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 16, 2014

Ministry of Health. BC Chronic Disease and Selected Procedure Case Definitions. Chronic Disease Information Working Group. Date Created: June 29, 2015

Updates to the Alberta Drug Benefit List. Effective May 1, 2018

20:00. Blood Formulation, Coagulation and Thrombosis. 20:00 Blood Formulation, Coagulation and Thrombosis

Updates to the Alberta Drug Benefit List. Effective July 1, 2018

UPDATE Z Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective August 04, 2011 SUMMARY OF CHANGES

SASKATCHEWAN FORMULARY BULLETIN. Update to the 60th Edition of the Saskatchewan Formulary

Therapeutic Substitution Service - Proton Pump Inhibitors (PPIs)

SASKATCHEWAN FORMULARY COMMITTEE BULLETIN TO THE 58th EDITION OF THE SASKATCHEWAN FORMULARY

SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN 52nd Edition

BULLETIN # 72. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on April 18, 2013

Product Name Strength Dosage Form Therapeutic Area Dossier Status. Aceclofenac 100mg Film coated Tablets Analgesia-inflammation Approved

Non-Insured Health Benefits

Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members

NB Drug Plans Formulary Update

Updates to the Alberta Drug Benefit List. Effective November 1, 2018

Updates to the Alberta Drug Benefit List. Effective October 1, 2017

New Exception Status Benefits

SASKATCHEWAN FORMULARY COMMITTEE BULLETIN UPDATE TO THE 57th EDITION OF THE SASKATCHEWAN FORMULARY

SUMMARY OF CHANGES. UPDATE 3 Ontario Drug Benefit Formulary/Comparative Drug Index No. 40 Effective July 12, 2007 TABLE OF CONTENTS.

Table 1: Price increases for Brand Name Drugs with Generic Equivalents

Products and Pricing on the Alberta Blue Cross Drug Price List (ABCDPL) Effective December 14, 2018

Step Therapy Requirements. Effective: 05/01/2018

Products and Pricing on the Alberta Blue Cross Drug Price List (ABCDPL) Effective February 14, 2019

BULLETIN # 65. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 14, 2010.

Updates to the Alberta Drug Benefit List. Effective July 1, 2017

Transcription:

Ontario Drug Benefit Formulary/ Comparative Drug Index Edition 42 Summary of Changes December 2013 Effective January 03, 2014 Ministry of Health and Long-Term Care

Table of Contents Additions to Formulary... 3 New Single Source Products... 4 New Multi-Source Products... 5 Off-Formulary Interchangeable (OFI) Products... 13 Not-A-Benefit (NAB) Products... 15 Changes to Current Formulary Products...16 Drug Benefit Price (DBP) Changes... 17 OFI Product Price Changes... 18 Manufacturer Requested Discontinued Products... 19 Product Manufacturer Name changes... 20 DIN/PIN Changes... 21 Removals from Formulary...22 Manufacturer Requested Delistings (General Benefit Products)... 23 Manufacturer Requested Delisting (OFI/NAB Product)... 24 2

Additions to Formulary 3

New Single Source Products DIN PRODUCT NAME GENERIC NAME MFR DBP 02391449 Cipralex MELTZ 10mg Orally Disintegrating Tab 02391457 Cipralex MELTZ 20mg Orally Disintegrating Tab Escitalopram VLH 1.7270 Escitalopram VLH 1.8387 4

New Multi-Source Products DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02404990 Auro-Anastrozole 1mg Tab AUR 1.2729 (Interchangeable with Arimidex) Reason for Use Code & Clinical Criteria Code 365 For the treatment of metastatic breast cancer in hormone receptor positive postmenopausal women. LU Authorization Period: Indefinite. Code 396 As an alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer. LU Authorization Period: Indefinite. 5

New Multi-Source Products (Cont d...) DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02404400 Auro-Letrozole 2.5mg Tab AUR 1.3780 (Interchangeable with Femara) Reason for Use Code & Clinical Criteria Code 365 For the treatment of metastatic breast cancer in hormone receptor positive postmenopausal women. LU Authorization Period: Indefinite. Code 403 For the treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. LU Authorization Period: 5 years. Code 408 As an alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer for a maximum of five years. LU Authorization Period: 5 years. 6

New Multi-Source Products (Cont d...) DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02411709 Auro-Mirtazapine 30mg Tab AUR 0.3100 (Interchangeable with Remeron) DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02404389 Co Dorzotimolol 2% & 0.5% Oph Sol COB 2.0951 (Interchangeable with Cosopt) Reason for Use Code & Clinical Criteria Code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. LU Authorization Period: Indefinite. Code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. LU Authorization Period: Indefinite. 7

New Multi-Source Products (Cont d...) DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02411954 Mar-Paroxetine 20mg Tab MAR 0.4514 02411962 Mar-Paroxetine 30mg Tab MAR 0.4796 (Interchangeable with Paxil) DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02408627 Mint-Montelukast 4mg Chew Tab MIN 0.3646 (Interchangeable with Singulair) Reason for Use Code & Clinical Criteria Code 382 For the treatment of asthma in patients aged 2-5 years old. LU Authorization Period: 1 year. 8

New Multi-Source Products (Cont d...) DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02387085 Ovima 21 0.03mg & 0.15mg Tab-21 Pk APX 7.2800 (Interchangeable with Min-Ovral 21) DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02387093 Ovima 28 0.03mg & 0.15mg Tab-28 Pk APX 7.2800 (Interchangeable with Min-Ovral 28) DIN BRAND NAME STRENGTH DOSAGE 02414090 Ran-Olanzapine ODT 5mg Rapid Dissolve Tab 02414104 Ran-Olanzapine ODT 10mg Rapid Dissolve Tab 02414112 Ran-Olanzapine ODT 15mg Rapid Dissolve Tab (Interchangeable with Zyprexa Zydis) MFR DBP RAN 0.8937 RAN 1.7857 RAN 2.6777 9

DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02403633 Teva- Alendronate/Cholecalciferol 70mg & 70mcg Tab TEV 2.7975 (Interchangeable with Fosavance) Note: The recommended dose of Vitamin D for osteoporosis prevention and treatment in adults over 50 years old is at least 800 IU/day, in conjunction with calcium. This product does not provide the total recommended daily intake of Vitamin D; supplemental Vitamin D may be required. The appropriate dosage of FOSAVANCE must be determined by the physician based on the patient's vitamin D requirement. DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02403641 Teva- Alendronate/Cholecalciferol 70mg & 140mcg Tab TEV 2.7975 (Interchangeable with Fosavance) DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02360101 Theo ER 400mg SR Tab AAP 0.3735 02360128 Theo ER 600mg SR Tab AAP 0.4524 (Interchangeable with Uniphyl) 10

New Multi-Source Products (Cont d...) DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02326035 Zinda-Anastrozole 1mg Tab STA 1.2729 (Interchangeable with Arimidex) Reason for Use Code & Clinical Criteria Code 365 For the treatment of metastatic breast cancer in hormone receptor positive postmenopausal women. LU Authorization Period: Indefinite. Code 396 As an alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer. LU Authorization Period: Indefinite. 11

New Multi-Source Products (Cont d...) DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02378213 Zinda-Letrozole 2.5mg Tab STA 1.3780 (Interchangeable with Femara) Reason for Use Code & Clinical Criteria Code 365 For the treatment of metastatic breast cancer in hormone receptor positive postmenopausal women. LU Authorization Period: Indefinite. Code 403 For the treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. LU Authorization Period: 5 years. Code 408 As an alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer for a maximum of five years. LU Authorization Period: 5 years. 12

Off-Formulary Interchangeable (OFI) Products DIN BRAND NAME STRENGTH DOSAGE MFR UNIT COST 02411946 Mar-Paroxetine 10mg Tab MAR 1.0430 (Interchangeable with Paxil) DIN BRAND NAME STRENGTH DOSAGE MFR UNIT COST 02408635 Mint-Montelukast 5mg Chew Tab MIN 0.5565 (Interchangeable with Singulair) DIN BRAND NAME STRENGTH DOSAGE MFR UNIT COST 02408643 Mint-Montelukast 10mg Tab MIN 0.8195 (Interchangeable with Singulair) 13

Off Formulary Interchangeable (OFI) Products (Cont d...) DIN BRAND NAME STRENGTH DOSAGE MFR UNIT COST 02414120 Ran-Olanzapine ODT 20mg Rapid Dissolve Tab RAN 7.4227 (Interchangeable with Zyprexa Zydis) DIN BRAND NAME STRENGTH DOSAGE MFR UNIT COST 02410338 Tetrabenazine Tablets 25mg Tab STE 4.8551 (Interchangeable with Nitoman) 14

Not-A-Benefit (NAB) Products DIN BRAND NAME STRENGTH DOSAGE MFR 02413809 Teva-Risedronate 150mg Tab TEV (Interchangeable with Actonel) 15

Changes to Current Formulary Products 16

Drug Benefit Price (DBP) Changes DIN BRAND NAME STRENGTH DOSAGE MFR DBP 02377721 Apo-Risedronate 150mg Tab APX 17.2600 02083523 Bezalip 400mg Tab AGP 2.1113 02362759 Gd-Amlodipine/Atorvastatin 5 mg & 10 mg Tab GEM 0.5802 02362767 Gd-Amlodipine/Atorvastatin 5 mg & 20 mg Tab GEM 0.6842 02362775 Gd-Amlodipine/Atorvastatin 5 mg & 40 mg Tab GEM 0.7232 02362783 Gd-Amlodipine/Atorvastatin 5 mg & 80 mg Tab GEM 0.7232 02362791 Gd-Amlodipine/Atorvastatin 10 mg & 10 mg Tab GEM 0.6125 02362805 Gd-Amlodipine/Atorvastatin 10 mg & 20 mg Tab GEM 0.7636 02362813 Gd-Amlodipine/Atorvastatin 10 mg & 40 mg Tab GEM 0.8000 02362821 Gd-Amlodipine/Atorvastatin 10 mg & 80 mg Tab GEM 0.8000 02185881 Kytril 1mg SR Tab HLR 10.0730 02291789 PMS-Risperidone ODT 1mg 02291797 PMS-Risperidone ODT 2mg Orally Disintegrating Tab Orally Disintegrating Tab PMS 0.5150 PMS 1.0188 02070847 Soriatane 10mg Cap AGP 2.1430 02070863 Soriatane 25mg Cap AGP 3.7637 17

OFI Product Price Changes DIN BRAND NAME STRENGTH DOSAGE MFR UNIT COST 02397307 Jamp-Pioglitazone 15mg Tab JPC 1.5716 02314568 Novo-Atomoxetine 18mg Cap NOP 2.6523 02240363 PMS-Polytrimethoprim 10000U/mL & Oph Sol- PMS 23.1900 1mg/mL 10mL Pk 02402807 Ran-Montelukast 5mg Chew Tab RAN 1.2075 02389517 Ran-Montelukast 10mg Tab RAN 1.7735 02375850 Ran-Pioglitazone 15mg Tab RAN 1.5716 02375869 Ran-Pioglitazone 30mg Tab RAN 2.2017 02375877 Ran-Pioglitazone 45mg Tab RAN 3.3105 02363062 Ran-Valsartan 40mg Tab RAN 0.5823 18

Manufacturer Requested Discontinued Products (Products will remain on Formulary for six months to facilitate depletion of supply) DIN BRAND NAME STRENGTH DOSAGE MFR 00396796 Apo-Haloperidol 0.5mg Tab APX 00663719 Apo-Propranolol 20mg Tab APX 02273551 PMS-Fenofibrate Micro 200mg Cap PMS 19

Product Manufacturer Name Changes DIN BRAND NAME STRENGTH DOSAGE Current MFR New MFR 02230434 Acet 120 120mg Sup PMS PEN 02230436 Acet 325 325mg Sup PMS PEN 02230437 Acet 650 650mg Sup PMS PEN 01916947 Bactroban 2% Oint GSK GCH 20

DIN/PIN Changes CURRENT DIN/PIN DIN/PIN BRAND NAME STRENGTH DOSAGE 09857353 02403420 Humalog Mix25 Kwikpen 25% & 75% Inj Susp- 5x3mL Pk MFR LIL 09857437 02242905 Midazolam Injection 5mg/mL Inj Sol-2mL Vial Pk PPC 21

Removals from Formulary (Removals from payment and listing) 22

Manufacturer Requested Delistings (General Benefit Products) DIN BRAND NAME STRENGTH DOSAGE MFR 02241797 Procytox 200mg Inj Pd-Vial Pk BAX 02241799 Procytox 1000mg Inj Pd-Vial Pk BAX 23

Manufacturer Requested Delisting (OFI/NAB Product) DIN BRAND NAME STRENGTH DOSAGE MFR 02370158 Piperacillin/Tazobactam 2g & 250mg Inj Pd-Vial Pk TEV powder for Inj. 24